Compare Adaptive Biotechnologies Corp (ADPT) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Teucrium Soybean Fund — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Teucrium Soybean Fund trades at $25.18. The key difference: Teucrium Soybean Fund is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | SOYB | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $22.37 | $25.36 |
52-Week Low | $10.24 | $21.07 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SOYB trades at $25.24, up 3.27% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Key support sits at $24 and resistance at $25. Recent news highlights potential tailwinds from China's $17 billion U.S. crop purchase pledge through 2028, which may benefit agricultural sectors including soybeans.
The stock's outlook is supported by positive technical momentum and favorable sector news, but investment appeal is tempered by a lack of available fundamental data on profitability and valuation. Risks include dependence on agricultural commodity cycles and trade policy stability. Investors should seek updated financials for a complete assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
